The objectives of AddNeuroMed are to use the consortium’s expertise in analytical techniques, pre-clinical and clinical development to provide technologies to facilitate and accelerate the delivery of safe and effective medicines whist addressing the issues of:
- Absence of diagnostic markers
- Lack of biomarkers of progression
- Lack of biomarkers of response/non-response
This project is aimed specifically at the discovery and validation of new markers for diagnostics, disease progression and therapeutic efficacy. The progression from in vitro to animal testing to the clinic is a blueprint for how similar approaches might be undertaken for other major diseases. The details are specific for Alzheimer Disease, but the approach can also be applied to other indications.